In a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from its pivotal ABTECT induction trials investigating obefazimod, a first-in-class oral miR-124 enhancer, for moderate to severely active ulcerative colitis. Abivax cashes in with a US$400m public offering following suite.
GSK licenses COPD blockbuster in US$12bn deal
Latest NewsFollowing Merck Sharp & Dohme (MSD)’s US$10bn acquisition of Verona Pharma and its potential COPD blockbuster Ohtuvayre®, GlaxoSmithKline (GSK) has secured a US$12bn deal for another PDE3/PDE4 inhibitor.
LIfT BioSciences Ltd receives €12m for clinical translation of IMANs
Latest NewsLIfT BioSciences Ltd, active in London, Galway and Houston, has been awarded a grant of €12m from the Disruptive Technologies Innovation Fund (DTIF) to support the clinical translation of its Immuno-Modulatory Alpha Neutrophils (IMANs). This funding will enable the preparation of the world’s first allogeneic therapy using synthetically programmed neutrophil granulocytes for Phase I trials.
It is time to rethink biotech scaling
BackgroundBiomanufacturing promises domestic, sustainable, sovereign and resilient production. Capacities are trapped in outdated scale-up processes. SPRIND urges investment and disruptive innovation to propel biomanufacturing. Demands are decentralised, non-sterile & continuous biomanufacturing capabilities.
Import tariff of 15%: significant implications for pharmaceutical firms
Latest NewsIn the ongoing dispute over US import tariffs on European pharmaceuticals, the European Commission has acquiesced to a 15% tariff on EU pharmaceutical exports to the United States, as well as to the imposition of the same rate on EU investments exceeding US$600m in the US, without formal resistance. Industry associations have reacted with strong criticism.
Bayer targets leading position in HER2-positive NSCLC
Latest NewsThe potential blockbuster HER2 tyrosine kinase inhibitor sevabertinib, developed jointly by Bayer AG and the Broad Institute, is expected to be submitted for regulatory approval in China in Q3 2025 for the treatment of HER2-positive non-small cell lung cancer (NSCLC).
From Brisbane to London to Paris: Vicebio´s Sanofi deal
Latest NewsFrom Brisbane to London to Paris: Australian vaccine innovation sparks US$1.15 billion deal with french Sanofi with an additional US$450 million tied to clinical milestones and underscoring a major commitment to next-generation respiratory vaccines.
Abivax soars 500% on TOP-Line data
Latest NewsIn a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from its pivotal ABTECT induction trials investigating obefazimod, a first-in-class oral miR-124 enhancer, for moderate to severely active ulcerative colitis. Abivax cashes in with a US$400m public offering following suite.
Westwards: AstraZeneca Shifts Gears with $50 Billion US Investment
Latest NewsAstraZeneca announces a US$50 billion investment in the USA amid pharma’s transatlantic drift. Virgina is set to become the multi-billion-dollar drug manufacturing hub.
Fine and speciality chemicals industry keeps its cool
BackgroundResilience and quality connections define Chemspec Europe 2025.
Eight healthy children born with DNA from three people
BackgroundA landmark study in the UK shows that mitochondrial replacement therapy can prevent babies from inheriting diseases caused by mutant mitochondria.